HEC169584 not checked
Sunshine Lake Pharma Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Each dose of HEC83518 will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.”In the company’s words, NCT07099118 on ClinicalTrials.gov
- Tested for
- Non - Alcoholic Steatohepatitis
- Main trialPhase 1
- “The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .”In the company’s words, NCT07099118 on ClinicalTrials.gov
Other drugs for Non - Alcoholic Steatohepatitis
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- Efimosfermin AlfaGSK · Phase 3
- PegozaferminHoffmann-La Roche · 89bio, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- SemaglutideNovo Nordisk · Phase 3
Coming up1
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Dec 2026 | A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026